Form 4 for STOK Stoke Therapeutics, Inc.
Accepted 2025-06-06 00:00:00 ET · period of report 2025-06-04 · accession 0001062993-25-011153 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-06-06 | 2025-06-04 | STOK | Skorpios Trust | 10% | S - Sale | $10.20 | -3.00M | 3.91M | -43% | -$30.60M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-04 | S | D | 3,000,000 | $10.20 | 3,906,181 | I See Footnote | — | — | (F1) Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,967,621 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 938,560 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein. |